Results 151 to 160 of about 902 (167)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid

Journal of Clinical Medicine, 2021
Zsuzsanna Lengyel, Timea BERKİ, Peter Olah   +2 more
exaly  

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021
Michael Anthonius Lim, Arief Wibowo, Henny Juliastuti   +2 more
exaly  

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

Clinical Therapeutics, 2008
Aziz Karim
exaly  

Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling

European Journal of Medicinal Chemistry, 2017
Anne-Marie Lambeir, Liliane Schoofs, Walter Luyten   +2 more
exaly  

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature

Frontiers in Immunology, 2018
Yosuke Mai, Kentaro Izumi, Wataru Nishie   +2 more
exaly  

Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

Journal of the American Heart Association, 2015
Kazunori Shimada, , Kikuo Isoda
exaly  

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

Expert Opinion on Pharmacotherapy, 2013
Masanori Abe, Kazuyoshi Okada, Noriaki Maruyama   +2 more
exaly  

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

Current Medical Research and Opinion, 2009
Richard Pratley
exaly  

Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema - An Overlooked Adverse Drug Reaction?

Current Diabetes Reviews, 2018
Christian Von Buchwald, Lise Aagaard
exaly  

Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180

Frontiers in Immunology, 2019
Yosuke Mai, Kentaro Izumi, Wataru Nishie   +2 more
exaly